ACADIA PHARMACEUTICALS INC. Stock Issued During Period, Shares, Employee Stock Purchase Plans
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ACADIA PHARMACEUTICALS INC. stock issued during period, shares, employee stock purchase plans for fiscal 2015 was 68.79K shares, a 29.74% decline from fiscal 2014.
- ACADIA PHARMACEUTICALS INC. stock issued during period, shares, employee stock purchase plans for fiscal 2014 was 97.91K shares, a 20.30% decline from fiscal 2013.
- ACADIA PHARMACEUTICALS INC. stock issued during period, shares, employee stock purchase plans for fiscal 2013 was 122.85K shares, a 40.32% decline from fiscal 2012.
- ACADIA PHARMACEUTICALS INC. stock issued during period, shares, employee stock purchase plans for fiscal 2012 was 205.86K shares, a 8.42% increase from fiscal 2011.
| Period end | Stock Issued During Period, Shares, Employee Stock Purchase Plans 3 month | Stock Issued During Period, Shares, Employee Stock Purchase Plans 12 month |
|---|---|---|
| 2015-12-31 | 68.79K shares 10-K · filed 2016-02-29 | |
| 2014-12-31 | 97.91K shares 10-K · filed 2016-02-29 | |
| 2013-12-31 | 122.85K shares 10-K · filed 2016-02-29 | |
| 2012-12-31 | 205.86K shares 10-K · filed 2015-02-26 | |
| 2011-12-31 | 189.88K shares 10-K · filed 2014-02-27 | |
| 2010-12-31 | 81.03K shares 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |